Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

WATERS CORPORATION

Waters Corp. designs, manufactures, sells and services ultra performance liquid chromatography (UPLC), high performan... read more Featured Products: More products

Download Mobile App




Blood Test Potentially Predicts Alzheimer’s Disease

By LabMedica International staff writers
Posted on 03 Jun 2014
A blood test has the potential to predict Alzheimer’s disease before patients start showing symptoms and it could be the key to curing this devastating illness.

Current biomarkers for Alzheimer’s disease (AD) are limited because they are time consuming, invasive or expensive and while blood-based biomarkers may be a more attractive option, none can currently detect preclinical AD with the required sensitivity and specificity.

Scientists at Georgetown University Medical Center (Washington DC, USA) enrolled cognitively healthy adults age 70 years and older, in a five year observational study. More...
Over the course of the study, 74 participants met criteria for amnestic mild cognitive impairment (aMCI) or mild Alzheimer's disease (AD). Blood samples were taken from selected participants.

To measure the biomarkers the team used liquid chromatography–mass spectrometry methods using an Acquity H-class Ultra Performance Liquid Chromatography (UPLC) system and mass spectrometry was performed on a quadrupole time-of-flight (Q-TOF) instrument, the Xevo G2 QTOF (Waters Corporation, Milford, MA, USA). Targeted metabolomic analysis of plasma samples was performed using the Absolute-IDQ P180 kit (BIOCRATES; Innsbruck, Austria).

The investigators discovered and validated a set of ten lipids from peripheral blood that predicted phenoconversion to either amnestic mild cognitive impairment or Alzheimer's disease within a two to three year timeframe with over 90% accuracy. This biomarker panel, reflecting cell membrane integrity, may be sensitive to early neurodegeneration of preclinical Alzheimer's disease.

Janet B. Kreizman, BA, the CEO of the American Association for Clinical Chemistry (AACC), said, “This discovery is a potentially enormous breakthrough in the fight against Alzheimer's. If research aimed at a cure for Alzheimer's is to move forward, it is crucial that Alzheimer's clinical trials find a way to recruit patients who are still asymptomatic, since they are the ones most likely to respond to treatment.” The expanded study will be presented at the upcoming AACC Annual Meeting & Clinical Lab Expo, which will be held July 27–31, 2014 in Chicago (IL, USA).

Related Links:

Georgetown University Medical Center 
Waters Corporation 
BIOCRATES



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Collection and Transport System
PurSafe Plus®
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Blood Glucose Test Strip
AutoSense Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: When assessing the same lung biopsy sample, research shows that only 18% of pathologists will agree on a TCMR diagnosis (Photo courtesy of Thermo Fisher)

Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection

Lung transplant recipients face a significant risk of rejection and often require routine biopsies to monitor graft health, yet assessing the same biopsy sample can be highly inconsistent among pathologists.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.